Pamela Harris appointed to lead Diabetes Sales, Managed Care and Government
Accounts on national level
PRINCETON, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Novo Nordisk, a healthcare company with an 85-year history of innovation and achievement in diabetes care, today announced the company has appointed Pamela Harris as vice president for Diabetes Sales, Managed Care and Government Accounts, effective immediately.
Harris, who since 2005 shared responsibility for managing the diabetes field force, will assume an expanded role of leading the company's 2,000-person field organization of representatives and managed market account executives.
"Pam has developed an impressive and successful track record in sales, managed healthcare, training and marketing," said Jerzy Gruhn, president of Novo Nordisk, Inc. "Her leadership style and strong business experience will help us continue to grow our company and help change the lives of millions of people living with diabetes."
Harris joined Novo Nordisk in 2005 after leading one of the national sales teams at Novartis Pharmaceuticals. In her 28 years in the pharmaceutical industry, she has held various positions in sales leadership roles, training, and marketing. Harris has received several awards recognizing her achievements. At Bristol-Myers Squibb, she was recognized for outstanding leadership and selected from 800 nominees worldwide to receive the Bristol-Myers Squibb Leadership Development Award. Additionally, she has been honored by the Harlem YWCA and was the recipient of their Black Achiever in Industry Award.
Harris received a Bachelor's degree from the College of New Jersey (formerly Trenton State College).
About Novo Nordisk
Novo Nordisk is a healthcare company with an 85-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.
|SOURCE Novo Nordisk|
Copyright©2008 PR Newswire.
All rights reserved